The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Aug. 22, 2017
Filed:
Mar. 29, 2016
Applicant:
Keyview Labs, Inc., Tampa, FL (US);
Inventor:
Josh Reynolds, Laguna Beach, CA (US);
Assignee:
KeyView Labs, Inc., Tampa, FL (US);
Primary Examiner:
Int. Cl.
CPC ...
A01N 43/40 (2006.01); A01N 43/42 (2006.01); A61K 31/439 (2006.01); A61K 31/205 (2006.01); A61K 31/22 (2006.01); A61K 31/473 (2006.01); A61K 31/197 (2006.01); A61K 31/4375 (2006.01); A61K 31/4748 (2006.01); A61K 45/06 (2006.01); A61K 9/28 (2006.01); A61K 31/19 (2006.01); A61K 31/221 (2006.01); A61K 31/4188 (2006.01); A61K 36/41 (2006.01); A61K 9/00 (2006.01); A61K 9/50 (2006.01); A61K 31/385 (2006.01); A23L 33/105 (2016.01); A23L 33/175 (2016.01); A23L 33/21 (2016.01);
U.S. Cl.
CPC ...
A61K 31/439 (2013.01); A23L 33/105 (2016.08); A23L 33/175 (2016.08); A23L 33/21 (2016.08); A61K 9/0053 (2013.01); A61K 9/28 (2013.01); A61K 9/50 (2013.01); A61K 31/19 (2013.01); A61K 31/197 (2013.01); A61K 31/205 (2013.01); A61K 31/22 (2013.01); A61K 31/221 (2013.01); A61K 31/385 (2013.01); A61K 31/4188 (2013.01); A61K 31/4375 (2013.01); A61K 31/473 (2013.01); A61K 31/4748 (2013.01); A61K 36/41 (2013.01); A61K 45/06 (2013.01); A23V 2002/00 (2013.01);
Abstract
Compositions and methods are provided that enhance cognition in a human to which the composition is orally administered. Remarkably, clinical studies have proven that contemplated compositions achieved the desired effects using a minimal number of active ingredients at or near threshold active dosages, wherein such compositions almost exclusively comprise huperzine A, vinpocetine or, and acetyl-L-carnitine, and optionally further include alpha lipoic acid,, and biotin.